Microtubule associated serine threonine like kinase (MASTL) has been recently identified as an important regulator of mitosis. By inhibiting protein phosphatase 2A, it plays a crucial role in activating one of the most important mitotic kinases known as cyclin dependent kinase1 (CDK1). MASTL has been seen to be up regulated in various types of cancers and is involved in tumor recurrence. It is activated by CDK1 through its auto regulatory loop but the complete mechanism of its activation is still unclear. In this study, we evaluated the regulation of MASTL via AKT during mitosis. Here we report that AKT phosphorylates MASTL at T299 which plays a critical role in its activation. Our results suggest that AKT increases CDK1 mediated phosphorylation and hence activity of MASTL which in turn promotes cell proliferation.. We also show that the oncogenic potential of AKT is augmented by MASTL activation as the AKT mediated oncogenesis in colorectal cell lines can be attenuated by inhibiting and/or silencing MASTL. In brief, we report that AKT has an important role in the progression of mitosis in mammalian cells and it does so through the phosphorylation and activation of MASTL.
Introduction
Microtubule associated serine threonine kinase like (MASTL) is known to be one of the main proteins that is essential for mitotic entry in mammalian cells [1] . It is required for timely activation of mitosis by activating CDK1/cyclin B complex via inhibition of protein phosphatase 2A (PP2A) [2] . PP2A is one of the major cellular serine threonine phosphatases that regulates number of signaling pathways [3] , as well as cell cylce progression. It is a very complex enzyme and consists of three subunits: the structural A subunit, the catalytic C subunit and the regulatory B subunit, forming a trimeric holoenzyme ABC complex. Each of the three subunits is in turn composed of many isoforms, the most complex being the B subunit. It is believed that the specific combination of the three subunit isoforms imparts specific function to a particular PP2A complex within the cell. The B subunit is the most diverse subunit in PP2A and has very critical role for giving specific localization and function to the enzyme. Among them, PP2A-B55δ isoform is known to be responsible for the dephosphorylation of CDK1 downstream targets to prevent premature mitotic entry [4] . It has been reported that Greatwall kinase, an orthologue of human MASTL, phosphorylates ARPP19 (19 kDa) and endosulphine-α (15 kDa, a ligand for sulphonyl urea receptor) at Serine 62 and Serine 67 respectively [5, 6] . After being phosphorylated by Greatwall kinase, these proteins strongly associate with PP2A-B55δ, thus resulting in the inhibition of this phosphatase [6] . Inhibition of PP2A is essential for mitotic entry of mammalian cells, as it facilitates the phosphorylation mediated activation of numerous proteins like CDK1/cyclin B, Plk1, AurK etc. which play critical role in mitotic entry and progression [7] . More evidences have shown that MASTL is necessary for recruitment of cyclin B to anaphase promoting complex (APC) at late metaphase. The timely degradation of cyclin B at this step is necessary for the transition of cells from metaphase to anaphase [8] .
In addition to its role at mitotic entry, MASTL plays an important role in mitotic exit as well, where upon its deactivation has been seen to be an essential requirement for the cells to exit from mitosis [9, 10] . Being so critical for mitosis, MASTL has been investigated in various types of carcinomas and has been seen to be up regulated in a number of malignancies [11] [12] [13] . Role of MASTL in tumor progression has been attributed to the increased rate of cell proliferation driven by activation/up-regulation of this kinase in tumor cells. Some recent evidences have also shown that MASTL promotes tumor formation and invasiveness via activation of AKT. MASTL has been observed to stabilize S473 phosphorylation of AKT by activating GSK3 which results in the ubiquitination of PHLPP, a phosphatase responsible for dephosphorylation of AKT on 473 [14] . Moreover, some high throughput studies have shown that MASTL can be a better therapeutic target to prevent tumor progression and resistance developed against anti-cancer drugs [11, 15, 16] . Taken together, MASTL regulation is critical for cells both in terms of correct timing of mitotic entry as well as regulation of normal cell proliferation to avoid tumor progression. However, the detailed mechanism of its regulation is still not clear. Although it has been shown that CDK1-cyclin B and more likely Plx1 kinase are responsible for phosphorylating and activating MASTL, but the complete network of its regulation is still not well understood [17] .
Here we report that following phosphorylation and activation by CDK1-cyclin B, MASTL is phosphorylated by AKT at T299. This phosphorylation leads to the further stabilization of CDK1-cyclin B mediated phosphorylation and hence activation of MASTL. Moreover, co-expression of MASTL and AKT in HEK293T cells and in SW480, a colorectal cancerous cell line, significantly increases mitotic index of these cells. We also show that the oncogenic potential of MASTL increases substantially in presence of AKT. Together, these results show that MASTL is a bona fide substrate of AKT and the role of AKT in tumorigenesis may largely occur through the activation of MASTL. These results also highlight an unknown role of AKT in the regulation of mitosis in mammalian cells.
Results

MASTL is a potential target for AKT.
In order to get an understanding of the functions of MASTL, we used Scansite, (www.scansite3.mit.edu), an online computational tool to look for kinases that could potentially target MASTL to regulate its activity. The results indicated that MASTL could be a possible substrate for AKT, as it has a perfect consensus site for AKT phosphorylation (RXRXXS/T) at T299, where R represents Arginine, X any aminoacid, S Serine and T Threonine ( Figure S1A ). A comparison of the sequences from different mammalian species using ClustalW software (https://www.ebi.ac.uk/Tools/msa/clustalo) showed that this site is highly conserved in many mammalian species ( Figure S1B ). To directly test whether MASTL is a bona fide substrate for AKT, we co-transfected pCMV-HA-MASTL with increasing amounts of pCDNA3.1-HA-AKT in HEK 293T cells. Results showed that at higher expression of AKT, MASTL protein levels were markedly reduced ( Figure 1A-B) . This was probably because AKT phosphorylates MASTL at its consensus motif due to which it is subjected to proteasomal degradation. To test whether that is so, we mutated MASTL (Mut-MASTL) at Threonine 299 to Alanine (T299A) ( Figure S1C ) and co-transfected it with increasing amounts of AKT. Our results showed that mutant MASTL (T299A) protein was not degraded even after the addition of 1.5µg of AKT DNA to HEK 293T cells ( Figure 1C-D) . To check whether MASTL protein degradation was due to AKT mediated phosphorylation followed by proteasomal degradation, we used bortezomib, an anticancer drug that inhibits proteasomes. Results showed that after the addition of 1µM bortezomib to HEK 293T cells for 24 hours, MASTL protein levels were stabilized back to normal levels ( Figure 1E ). Furthermore, to confirm that AKT is responsible for MASTL protein degradation, LY294002, a wellknown inhibitor of PI3K/AKT pathway was used to inhibit AKT activation in these cells.
As can be seen from the Figure 1F , protein levels of MASTL were restored to normal levels by the addition of 20µM LY294002 to HEK293T even in presence of AKT.
Moreover, a kinase dead mutant (KD) of AKT (pCDNA3-T7-AKT1-K179M-T308A-S473A) did not affect MASTL protein levels much when transiently expressed in HEK 293Ts ( Figure 1G-H) . In support of these results, coexpression of a hyperactive catalytic subunit of PI3 kinase mutant (H1056R) with wild type MASTL in HEK293 T cells degraded MASTL protein levels to similar extent as that of wild type AKT ( Figure 1I -J).
From these findings, it was confirmed that MASTL protein degradation was caused by AKT.
MASTL is phosphorylated by AKT on its substrate site.
The proteasomal degradation of MASTL in presence of AKT implied that MASTL might be phosphorylated by AKT. Therefore, our next aim was to directly confirm whether AKT phosphorylates MASTL on its substrate site. pCMV-HA-MASTL and pCDNA3.1-HA-AKT were co-transfected in HEK 293T cells and untransfected cells were taken as control. This was followed by immunoprecipitation of exogenously expressed HA-MASTL using anti-HA antibody. The immunoprecipitated proteins were blotted with anti phospho-AKT substrate antibody. This antibody recognizes the potential substrates that are phosphorylated by AKT on its consensus site (RXRXXS/T).
As can be seen from Figure 2A , the phosphorylation signal for AKT substrate is very strong in MASTL/AKT co-transfected lane as compared to the MASTL lane (Figure 2A ).
The same blot was reprobed using anti-HA antibody in order to confirm the presence of MASTL and AKT in all the lanes. ( Figure 2B ). To further confirm whether the phosphorylation was done by AKT specifically at its substrate site on MASTL, AKT was co-transfected with mutant MASTL (T299A) as well as wild type MASTL. After transfection, protein lysates were again subjected to immunoprecipitation using anti HA antibody to pull down HA-MASTL protein. Following Western blotting, the blot was probed using anti-phospho AKT substrate antibody. Our results clearly showed that anti-phospho AKT antibody specifically detected wild type MASTL but not the mutant MASTL (T299A) when co-transfected with AKT ( Figure 2C ). The same blot was reprobed with anti-HA antibody to detect the presence of other transfected proteins ( Figure 2D ).
AKT phosphorylates MASTL and increases CDK1 substrate phosphorylations during mitotic progression.
From the above results, it was confirmed that AKT phosphorylates MASTL at T299 residue. Since MASTL is a mitotic protein and is required in its active form only during mitosis, so we asked whether MASTL would be phosphorylated by AKT only during mitosis. To check that, we co-transfected MASTL and AKT in HEK 293T cells and arrested them in mitosis using 50nM nocodazole for 18 hours. Western blotting results indeed confirmed that AKT phosphorylates MASTL during mitotic phase as was indicated by a distinct band shift on MASTL ( Figure 3A ). 
Discussion
For the continuous proliferation of tumor cells, mitotic proteins are either upregulated or hyperactivated to promote mitosis [18] . Hence, these proteins have been always found to be interesting and effective targets to overcome cellular proliferation of tumor cells [19] . Microtubule associated serine threonine kinase like (MASTL) is one of the important regulators of mitosis that was discovered a few years ago. The mutated form of MASTL has been seen to be implicated in thrombocytopenia, and up-regulation of this protein has been observed in various cancers [20, 21] . The mechanism of MASTL in cell cycle regulation and cancer progression is still not very well understood.
Though there are various studies regarding its role in cell cycle, the understanding of its regulation during mitosis is still poor. There are only a couple of studies that have reported that MASTL is regulated mainly by CDK1 whereas Plx1 can substitute CDK1 by phosphorylating and activating MASTL at the same phosphorylation site at least in vitro. The same study has reported that besides CDK1, there might be some other regulators of MASTL potentially from its own AGC family members [22, 23] . We compared the impact of both RSK and AKT on MASTL activity and showed that AKT has more impact on MASTL phosphorylation than RSK, thus suggesting that MASTL could be the bona fide taget for AKT in vivo.
In order to better understand the process of cancer progression and developing new therapeutic targets against this disease, studying the regulation and role of new targets like MASTL is of great importance. Therefore, in this study we attempted to elucidate the mechanism of MASTL during mitosis. We employed www.scansite3.edu, an online computational software to search for potential regulators of MASTL and found out that AKT could be one of the regulators of this kinase. Interestingly, MASTL has a perfect consensus site for AKT phosphorylation which is conserved between various mammalian species that prompted us to investigate these findings further. We overexpressed MASTL and AKT together in HEK293T cells and found that MASTL protein is degraded after co-expressing with AKT. Using various chemical inhibitors like bortezomib and LY294002, we observed that the degradation is mediated by proteasomes. Further biochemical assays showed that AKT phosphorylates MASTL on T299 during mitosis. Moreover, AKT mediated phosphorylation of MASTL during mitosis leads to increase in the phosphorylations of CDK1 downstream substrates with a significant increase in phosphorylation of MASTL. It has been observed that various phosphorylations at the N-terminal and C-terminal domain of MASTL lead these two lobes to interact with each other which results in the stabilization of phosphorylations of this kinase [17] . Our results also demonstrate similar mechanism for AKT mediated phosphorylation on MASTL which results in the stabilization of CDK1 mediated phosphorylation of this kinase, leading to its further activation. In contrast, higher expression of AKT leads to the increased degradation of CDK1 substrates.
Furthermore, stable expression of AKT in SW480 colorectal cell line that has high expression of MASTL, increased the proliferation of these cells. This increase in SW480-AKT cell growth was reduced by silencing of MASTL as well as AKT in these cells. Moreover, as shown by FACS analysis, AKT enhances the mitotic cell population of SW480 cell line which was seen to be reversed by silencing of MASTL. These findings suggest that overexpression of AKT in SW480 cell line leads to the activation of MASTL which promotes the entry of cells into mitosis.
Our data supports the findings of an earlier report that mentions that GWL leads to the activation of AKT [14] . In this paper, the authors have shown evidence that GWL indirectly leads to the enhanced phosphorylation of AKT at S473, leading to its activation. It does so by an unknown mechanism that stimulates the dephosphorylation and activation of GSK3, which phosphorylates PHLPP at numerous sites, promoting its degradation by the SCF-β-TRCP proteasomal complex. Since PHLPP phosphatase is known to dephosphorylate AKT at S473, hence its degradation by GWL results in the sustained phosphorylation and activation of AKT. Our studies have shown the reciprocal mechanism. We showed evidence that AKT directly phosphorylates MASTL at T299 residue, leading to its activation which leads to the enhanced entry of cells into mitosis.
It is possible that both AKT and MASTL reciprocally phosphorylate and activate each other by feed back mechanisms, and thus promote cellular transformation. Though both kinases have been individually seen to be activated in cancers, it will be interesting to see whether both kinases are activated in tumors at the same time. The phosphorylation may occur during a short lived transient interaction between them as we were not successful in finding an interaction between AKT and MASTL in immunoprecipitation experiments (data not shown).
In summary, our findings demonstrate that MASTL is phosphorylated by AKT during mitosis which leads to the further activation of MASTL. Also, elimination of MASTL can overcome uncontrolled cellular proliferation of both MASTL as well as AKT overexpressing cancerous cells. These results assume significance since both AKT and MASTL are reported to be activated and/or overexpressed in many types of cancers and are popular targets for anti-cancer therapy. Since AKT regulates numerous signaling pathways including cell survival pathways, using pan anti-AKT drugs can have toxic effects on the cells and patients. On the other hand, identifying and inhibiting specific downstream candidates like MASTL that regulate mitotic progression may prove to more beneficial as anti-cancer tehrapeutic agents. Q5-high fidelity DNA polymerase, dNTPs, T4 DNA ligase, DpnI and all restriction enzymes that were used in our experiments were purchased from New England Biolabs, USA. Transfection reagent Polyethaneamine (PEI) was obtained from Polysciences, USA. MASTL construct was obtained from Anna Castro, France [22] , amplified by PCR using adaptors containing XhoI and NotI restriction sites and was later cloned into pCMV-HA-3.7, using the primer sequences: MASTL (5´-GGCCTCGAGTAG ATCCCACCGCGGGAAGCAA-3´ and 3´-GGCCGCGGCCGCCTACAGACTAAATCCA GATAC-5´) by following standard cloning procedures. pCDNA3.1 HA-AKT1 (Addgene plasmid # 9008) [24] , PKH3 human RSK (Addgene plasmid # 13841) [25] , pCDNA3 T7 AKT1 K179M T308A S473A (Addgene plasmid # 9031) [24] . PI3K (H1056R), HEK293T, Pheonix and SW-480 cell lines were kindly given as gift items by Prof. Thomas Roberts, DFCI, Harvard University, USA. shAKT1 and shAKT2 were cloned in pLKO.1 puro using the following sequences: shAKT1: CGCGTGACCATGAACGAGTTT and shAKT2:
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CGAGTTTGAGTACCTGAAGCT [26] . Western Blotting.
Site directed mutagenesis
The denatured cell lysates were run in SDS-PAGE and the proteins were transferred onto nitrocellulose membrane. Following this, the blots were blocked with 5% non-fat dry milk for about 1 hour. After that, corresponding primary antibodies were added to each blot and incubated overnight at 4 o C. Subsequently, washing of blots was done three times by 1x TBS-T (NaCl 13.7mM, Tris 20mM; pH 7.4, Tween-20, 0.05%) for 10 minutes each. This was followed by incubation of blots in secondary antibody for about 1 hour. Finally, the blots were again washed three times with 1xTBS-T and subjected to infrared detection system using LICOR machine.
Immunoprecipitation
Anti-HA antibody was premixed with protein G agarose beads in the ratio of 1:20. The antibody and bead mixture were kept on a rotator for about 1hr at 4 o C. The preloaded beads were then washed three times with 1x PBS at 3,000 rpm for 1 minute each. Equal amount of each protein extracts (as measured by Bradford assay) were added to the protein G Agarose beads pre-loaded with primary antibody. The samples were incubated/mixed overnight on a rotator at 4 o C. After incubation, the beads were washed three times with 1x PBS at 3,000 rpm for 1 minute each. Finally, 2x loading buffer was added to the beads and the mixtures were boiled at 100 o C for 3-5 minutes. The samples were then subjected to Western blotting.
Crystal violet.
Equal number of cells (1x10 5 ) were seeded in 6 well plates. Next day, the induction of shMASTL, shAKT1 and shAKT2 with 20µg/mL doxycycline was done for 24 hours after which the plates were taken and washed once with 1xPBS. Following that, cells were fixed with methanol for 10 minutes and washed again with 1xPBS. 1 mL of 0.1% crystal violet (0.1% crystal violet in 25% ethanol) was added per well and left in the wells for about 10 minutes at room temperature. The dye was then aspirated from the plates, followed by washing with distilled water. The stained cells were allowed to dry at room temperature. For quantification, the dye attached to the cells was extracted with 2mL of 10% acetic acid, and its absorbance was measured at 590nm. Experiments were done in duplicates and were repeated three times.
MTT assay.
Equal number of cells (10,000) were plated in 12 well plates. After reaching to 50% cell density, the induction of shMASTL, shAKT1 and shAKT2 with 20µg/mL doxycycline was done for 24 hours. Next, the medium of cells was replaced with fresh medium and 100µL of 12mM MTT stock (5mg MTT in 1mL 1x PBS) was added to each well. After incubating the cells with MTT for about 2 hours in CO 2 incubator at 37 o C, 1mL of SDSHCl (5 gm of SDS in 50mL 0.01M HCl) solution was added to each well. The solutions were mixed thoroughly by pipetting and incubated again at 37 o C for about 4 hours. Next, the plates were removed from the incubator, the solutions were again mixed by pipetting and the absorbance was measured at 570nm.
FACS analysis.
For cell cycle analysis, cell lines were grown up to 60-70% density. 
